Journal
IMMUNOTHERAPY
Volume 1, Issue 5, Pages 795-807Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.09.48
Keywords
cervical cancer prevention; cervical cancer screening; HPV DNA testing; HPV vaccine; human papillomavirus
Categories
Ask authors/readers for more resources
Despite the available knowledge and tools to prevent cervical cancer, it remains the second most common cancer in women, with four-fifths of the cases occurring in developing countries. Projections are for a 90% increase in global cervical cancer cases by 2020 if no additional public-health interventions are implemented. Prophylactic human papillomavirus (HPV) vaccines, which have proven immunogenicity, safety and efficacy, are now commercially available; and coupled together with quality screening have the potential to dramatically accelerate reductions in cervical cancer mortality rates and save millions of women's lives. The current cost of the new HPV vaccines and new screening technologies, however, are a major barrier to their widespread implementation. There is an urgent need for HPV vaccines and new technologies for effective screening to become more available and affordable, especially to poor communities everywhere.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available